Innovative polymeric and non-polymeric nanocarrier systems for dexamethasone: enhancing precision and reducing side effects
Source abstract
Abstract
Abstract Dexamethasone (DEX), a potent synthetic glucocorticoid, has long been recognized for its remarkable anti-inflammatory, immunosuppressive, and therapeutic potential across diverse medical domains. However, traditional delivery methods have been hindered by systemic toxicity, poor targeting, and limited efficacy. This comprehensive review explores cutting-edge drug delivery technologies that are revolutionizing DEX’s therapeutic landscape, offering unprecedented precision and enhanced clinical outcomes. The review systematically examines advanced carrier systems, including lipid-based nanoparticles, micelles, polymeric nanoparticles, cyclodextrin-based platforms, hyaluronic acid nanocarriers, hydrogels, carbon-based nanostructures, and inorganic nanostructures. These innovative approaches demonstrate remarkable capabilities in improving drug bioavailability, targeted delivery, sustained release, and minimized systemic side effects. Cutting-edge research highlights the transformative potential of these delivery systems across multiple therapeutic areas, including rheumatoid arthritis, inflammatory bowel disease, oncology, neurodegenerative disorders, bone regeneration, and ocular and respiratory treatments. By enhancing drug targeting, controlling release kinetics, and reducing adverse effects, these nanotechnology-driven platforms are poised to reshape DEX’s clinical applications, offering more precise and effective treatment strategies.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Overman RA, Yeh JY, Deal CL (2013) Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis care & research. 65(2):294–810.1002/acr.21796 ↗
2. Curtis JR et al (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Care Res 55(3):420–42610.1002/art.21984 ↗
3. RECOVERY Collaborative Group (2021) Dexamethasone in hospitalized patients with Covid-19. New England journal of medicine. 384(8):693–70410.1056/NEJMoa2021436 ↗
4. Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. New England J Med. 353(16):1711–2310.1056/NEJMra050541 ↗
5. Rutz HP, Herr I (2004) Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. Cancer Biol Ther 3(8):715–71810.4161/cbt.3.8.966 ↗
6. Schäcke H, Döcke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacology & therapeutics. 96(1):23–4310.1016/S0163-7258(02)00297-8 ↗
7. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, de Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R (2006) Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Annals of the rheumatic diseases. 65(3):285–9310.1136/ard.2005.038638 ↗
8. Vivek GK, Vaibhav N, Shetty A, Mohammad I, Ahmed N, Umeshappa H (2020) Efficacy of various routes of dexamethasone administration in reducing postoperative sequelae following impacted third molar surgery. Annals of Maxillofacial Surgery. 10(1):61–510.4103/ams.ams_66_19 ↗
9. Dubashynskaya, N.A.-O., A.A.-O. Bokatyi, and Y.A.-O. Skorik, Dexamethasone conjugates: synthetic approaches and medical prospects. LID - https://doi.org/10.3390/biomedicines9040341 LID - 341. (2227–9059 (Print)).10.3390/biomedicines9040341 ↗
10. Meka RR, Venkatesha SH, Acharya B, Moudgil KD (2019) Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy. Nanomedicine. 14(11):1455–6910.2217/nnm-2018-0501 ↗
11. Urbańska J, Karewicz A, Nowakowska M (2014) Polymeric delivery systems for dexamethasone. Life Sci 96(1):1–610.1016/j.lfs.2013.12.020 ↗
12. Truong D et al (2024) Advancements in hydrogel technology for ocular drug delivery. Exploration of BioMat-X 1(6):331–35210.37349/ebmx.2024.00023 ↗
13. Haghighi M, Khoshfetrat A (2021) Au-O-MWCNTs and TiO2-O-MWCNTs as efficient nanocarriers for dexamethasone: adsorption isotherms and kinetic studies. Int J Chem Eng 2021(1):2040363
14. Ebrahimi M, Akhavan O (2022) Nanomaterials for photocatalytic degradations of analgesic, mucolytic and anti-biotic/viral/inflammatory drugs widely used in controlling SARS-CoV-2. Catalysts. 12(6):66710.3390/catal12060667 ↗
15. Kilic I, Dagdeviren E, Kaya E (2008) Effects of neonatal dexamethasone or methylprednisolone on rat growth and neurodevelopment. Pediatr Int 50(4):489–49410.1111/j.1442-200X.2008.02588.x ↗
16. Misaka S et al (2011) Evaluation of the pharmacokinetic interaction of midazolam with ursodeoxycholic acid, ketoconazole and dexamethasone by brain benzodiazepine receptor occupancy. J Pharm Pharmacol 63(1):58–6410.1111/j.2042-7158.2010.01176.x ↗
17. Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ (2000) Dexamethasone induces pregnane X receptor and retinoid X receptor-α expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Molecular pharmacology. 58(2):361–7210.1016/S0026-895X(24)12072-X ↗
18. Scheving LA et al (2007) Dexamethasone modulates ErbB tyrosine kinase expression and signaling through multiple and redundant mechanisms in cultured rat hepatocytes. American Journal of Physiology-Gastrointestinal and Liver Physiology, 293(3):G552-G559.10.1152/ajpgi.00140.2007 ↗
19. de Brabander J et al (2022) Association between dexamethasone treatment and the host response in COVID-19 patients admitted to the general ward. Respir Res 23(1):14510.1186/s12931-022-02060-3 ↗
20. Li L et al (2012) A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats. Acta Pharmacol Sin 33(1):127–13610.1038/aps.2011.161 ↗
21. Bourdin V, Bigot W, Vanjak A, Burlacu R, Lopes A, Champion K, Depond A, Amador-Borrero B, Sene D, Comarmond C, Mouly S (2023) Drug–drug interactions involving dexamethasone in clinical practice: myth or reality? Journal of Clinical Medicine. 12(22):712010.3390/jcm12227120 ↗
22. Kim JH, Hwang YJ, Han SH, Lee YE, Kim S, Kim YJ, Cho JH, Kwon KA, Kim JH, Kim SH (2015) Dexamethasone inhibits hypoxia-induced epithelial-mesenchymal transition in colon cancer. World Journal of Gastroenterology: WJG. 21(34):988710.3748/wjg.v21.i34.9887 ↗
23. Ní Chonghaile T, Concannon CG, Szegezdi E, Gorman AM, Samali A (2006) Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-X L. Apoptosis. 11:1247–5510.1007/s10495-006-7233-1 ↗
24. Queckenberg C, Wachall B, Erlinghagen V, Di Gion P, Tomalik-Scharte D, Tawab M, Gerbeth K, Fuhr U (2011) Pharmacokinetics, pharmacodynamics, and comparative bioavailability of single, oral 2-mg doses of dexamethasone liquid and tablet formulations: a randomized, controlled, crossover study in healthy adult volunteers. Clinical therapeutics. 33(11):1831–4110.1016/j.clinthera.2011.10.006 ↗
25. Li H, Gou R, Liao J, Wang Y, Qu R, Tang Q, Gan J, Shi S (2023) Recent advances in nano-targeting drug delivery systems for rheumatoid arthritis treatment. Acta Materia Medica. 2(1):23–4110.15212/AMM-2022-0039 ↗
26. Lu H, Zhang S, Wang J, Chen Q (2021) A review on polymer and lipid-based nanocarriers and its application to nano-pharmaceutical and food-based systems. Frontiers in nutrition. 810.3389/fnut.2021.783831 ↗
27. Majumder J, Minko T (2021) Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert opinion on drug delivery. 18(2):205–2710.1080/17425247.2021.1828339 ↗
28. Liu G, Lovell JF, Zhang L, Zhang Y (2020) Stimulus-responsive nanomedicines for disease diagnosis and treatment. International journal of molecular sciences. 21(17):638010.3390/ijms21176380 ↗
29. Parvin N, Joo SW, Mandal TK (2025) Biodegradable and Stimuli-Responsive Nanomaterials for Targeted Drug Delivery in Autoimmune Diseases. J Func Biomat 16(1):2410.3390/jfb16010024 ↗
30. Mehta M et al (2023) Lipid-based nanoparticles for drug/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Materials Au 3(6):600–61910.1021/acsmaterialsau.3c00032 ↗
31. Rahim MA, Jan N, Khan S, Shah H, Madni A, Khan A, Jabar A, Khan S, Elhissi A, Hussain Z, Aziz HC (2021) Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting. Cancers. 13(4):67010.3390/cancers13040670 ↗
32. Wang X, Feng Y, Fu J, Wu C, He B, Zhang H, Wang X, Dai W, Sun Y, Zhang Q (2019) A lipid micellar system loaded with dexamethasone palmitate alleviates rheumatoid arthritis. AAPS Pharm Sci Tech. 20:110.1208/s12249-019-1449-1 ↗
33. Brito Barrera, Y.A., et al., Engineering osteogenic microenvironments by combination of multilayers from collagen type I and chondroitin sulfate with novel cationic liposomes. (2590–0064 (Electronic)).
34. Tentillier, N.A.-O.X., et al., Anti-inflammatory modulation of microglia via CD163-targeted glucocorticoids protects dopaminergic neurons in the 6-OHDA Parkinson’s disease model. (1529–2401 (Electronic)).
35. Li, S., et al., Anti-ICAM-1 antibody-modified nanostructured lipid carriers: a pulmonary vascular endothelium-targeted device for acute lung injury therapy. (1477–3155 (Electronic)).
36. Medina-Montano, C., et al., Nanostructured lipid carriers loaded with dexamethasone prevent inflammatory responses in primary non-parenchymal liver cells. LID - https://doi.org/10.3390/pharmaceutics14081611 LID - 1611. (1999–4923 (Print)).10.3390/pharmaceutics14081611 ↗
37. Chen H-H et al (2024) Solid lipid nanoparticles loaded with dexamethasone palmitate for pulmonary inflammation treatment by nebulization approach. Pharmaceutics 16(7):87810.3390/pharmaceutics16070878 ↗
38. Serpe, L., et al., Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. (1879–0720 (Electronic)).
39. Ohto, T., et al., Inhibition of the inflammatory pathway enhances both the in vitro and in vivo transfection activity of exogenous in vitro-transcribed mRNAs delivered by lipid nanoparticles. (1347–5215 (Electronic)).
40. Simion, V., et al., P-Selectin targeted dexamethasone-loaded lipid nanoemulsions: a novel therapy to reduce vascular inflammation. (1466–1861 (Electronic)).
41. Song, Y., et al., ROS-mediated liposomal dexamethasone: a new FA-targeted nanoformulation to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways. (2040–3372 (Electronic)).
42. Cerri, L.A.-O., et al., Cross-linked thiolated hydroxypropil-β-cyclodextrin for pulmonary drug delivery. LID - https://doi.org/10.3390/ijms25179394 LID - 9394. (1422–0067 (Electronic)).10.3390/ijms25179394 ↗
43. Zhao, Y.P., et al., Flexible nano-liposomes-based transdermal hydrogel for targeted delivery of dexamethasone for rheumatoid arthritis therapy. (1521–0464 (Electronic)).
44. Zhu, R., et al., Chondroitin sulfate and L-cysteine conjugate modified cationic nanostructured lipid carriers: pre-corneal retention, permeability, and related studies for dry eye treatment. (1879–0003 (Electronic)).
45. Wang, W., et al., Transferrin-PEG-PE modified dexamethasone conjugated cationic lipid carrier mediated gene delivery system for tumor-targeted transfection. (1178–2013 (Electronic)).
46. Pourmadadi M et al (2024) Polymeric nanoparticles as delivery vehicles for targeted delivery of chemotherapy drug fludarabine to treat hematological cancers. Inorg Chem Commun 167:11281910.1016/j.inoche.2024.112819 ↗
47. Rangasami, V.K., et al., Harnessing hyaluronic acid-based nanoparticles for combination therapy: a novel approach for suppressing systemic inflammation and to promote antitumor macrophage polarization. (1879–1344 (Electronic)).
48. Jadhav, D. and P. Vavia, Dexamethasone sodium phosphate loaded modified cyclodextrin based nanoparticles: an efficient treatment for rheumatoid arthritis. (1520–6017 (Electronic)).
49. Wang, Q., et al., Targeted delivery of low-dose dexamethasone using PCL-PEG micelles for effective treatment of rheumatoid arthritis. (1873–4995 (Electronic)).
50. Krishnan V et al (2013) Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. Mol Pharm 10(6):2199–221010.1021/mp300350e ↗
51. Alami-Milani, M., et al., Preparation and evaluation of PCL-PEG-PCL micelles as potential nanocarriers for ocular delivery of dexamethasone. (2008–3866 (Print)).
52. Racaniello, G.F., et al., Chitosan and anionic solubility enhancer sulfobutylether-β-cyclodextrin-based nanoparticles as dexamethasone ophthalmic delivery system for anti-inflammatory therapy. LID - https://doi.org/10.3390/pharmaceutics16020277 LID - 277. (1999–4923 (Print)).10.3390/pharmaceutics16020277 ↗
53. Tavares, M.T., et al., Platelet lysates-based hydrogels incorporating bioactive mesoporous silica nanoparticles for stem cell osteogenic differentiation. (2590–0064 (Electronic)).
54. Ullah, I.A.-O., et al., An osteogenic, antibacterial, and anti-inflammatory nanocomposite hydrogel platform to accelerate bone reconstruction. (2050–7518 (Electronic)).
55. Miao, Y., et al., Engineering natural DNA matrices with halloysite nanotubes to fabricate injectable therapeutic hydrogels for bone regeneration. (2214–031X (Print)).
56. Xu, W.A.-O., et al., Dexamethasone long-term controlled release from injectable dual-network hydrogels with porous microspheres immunomodulation promotes bone regeneration. (1944–8252 (Electronic)).
57. Bordini, E.A.-O., et al., Injectable multifunctional drug delivery system for hard tissue regeneration under inflammatory microenvironments. (2576–6422 (Electronic)).
58. Jaiswal, C., et al., Injectable anti-cancer drug loaded silk-based hydrogel for the prevention of cancer recurrence and post-lumpectomy tissue regeneration aiding triple-negative breast cancer therapy. (2772–9508 (Electronic)).
59. Pegoraro, N.S., et al., The association of oleic acid and dexamethasone acetate into nanocapsules enables a reduction in the effective corticosteroid dose in a UVB radiation-Induced sunburn model in mice. LID - https://doi.org/10.3390/pharmaceutics16020176 LID - 176. (1999–4923 (Print)).10.3390/pharmaceutics16020176 ↗
60. Zhang, Z., et al., Intra-articular injection of cross-linked hyaluronic acid-dexamethasone hydrogel attenuates osteoarthritis: an experimental study in a rat model of osteoarthritis. (1422–0067 (Electronic)).
61. Camara, C.I., et al., Hyaluronic Acid-dexamethasone nanoparticles for local adjunct therapy of lung inflammation. LID - https://doi.org/10.3390/ijms221910480 LID - 10480. (1422–0067 (Electronic)).10.3390/ijms221910480 ↗
62. Abdel-Emam RA et al (2024) Development and evaluation of dexamethasone-loaded bioadhesive polymeric nanocapsules for mitigating cardiac and gastric adverse effects of free dexamethasone. J Pharm Investig 54(6):825–84410.1007/s40005-024-00686-7 ↗
63. Lee, S.A.-O., et al., Facile preparation of β-cyclodextrin-grafted chitosan electrospun nanofibrous scaffolds as a hydrophobic drug delivery vehicle for tissue engineering applications. (2470–1343 (Electronic)).
64. Coimbra, M., et al., Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles. (1873–4995 (Electronic)).
65. Diab T et al (2020) Dexamethasone simulates the anticancer effect of nano-formulated paclitaxel in breast cancer cells. Bioorg Chem 99:10379210.1016/j.bioorg.2020.103792 ↗
66. Zhang, J., et al., An injectable thermosensitive hyaluronic acid/Pluronic F-127 hydrogel for deep penetration and combination therapy of frozen shoulder. (1879–0003 (Electronic)).
67. Zewail, M., N. Nafee, and N. Boraie, Intra-articular dual drug delivery for synergistic rheumatoid arthritis treatment. (1520–6017 (Electronic)).
68. Wang, Q.S., et al., Dexamethasone-loaded thermo-sensitive hydrogel attenuates osteoarthritis by protecting cartilage and providing effective pain relief. (2305–5839 (Print)).
69. Chen, Y., et al., Dexamethasone-loaded injectable silk-polyethylene glycol hydrogel alleviates cisplatin-induced ototoxicity. (1178–2013 (Electronic)).
70. Le, T.A.-O., et al., Injectable poloxamer hydrogel formulations for intratympanic delivery of dexamethasone. (1598–6357 (Electronic)).
71. López-Cano, J.J., et al., Thermo-responsive PLGA-PEG-PLGA hydrogels as novel injectable platforms for neuroprotective combined therapies in the treatment of retinal degenerative diseases. LID - https://doi.org/10.3390/pharmaceutics13020234 LID - 234. (1999–4923 (Print)).10.3390/pharmaceutics13020234 ↗
72. Annala, A., et al., Self-healing thermosensitive hydrogel for sustained release of dexamethasone for ocular therapy. (2694–2453 (Electronic)).
73. Ajaz, N., et al., In vitro and in vivo evaluation of hydroxypropyl-β-cyclodextrin-grafted-poly(acrylic acid)/poly(vinyl pyrrolidone) semi-interpenetrating matrices of dexamethasone sodium phosphate. LID - https://doi.org/10.3390/ph15111399 LID - 1399. (1424–8247 (Print)).10.3390/ph15111399 ↗
74. Ajaz, N., et al., In vitro and biological characterization of dexamethasone sodium phosphate laden pH-sensitive and mucoadhesive hydroxy propyl β-cyclodextrin-g-poly(acrylic acid)/gelatin semi-interpenetrating networks. LID - https://doi.org/10.3390/gels8050290 LID - 290. (2310–2861 (Electronic)).10.3390/gels8050290 ↗
75. Chauhan, N., et al., Dexamethasone-loaded, injectable pullulan-poly(ethylene glycol) hydrogels for bone tissue regeneration in chronic inflammatory conditions. (1873–0191 (Electronic)).
76. Argenziano, M., et al., Cyclodextrin-based nanohydrogels containing polyamidoamine units: a new dexamethasone delivery system for inflammatory diseases. LID - https://doi.org/10.3390/gels3020022 LID - 22. (2310–2861 (Electronic)).10.3390/gels3020022 ↗
77. Zhang Y et al (2023) Hyaluronic acid modified oral drug delivery system with mucoadhesiveness and macrophage-targeting for colitis treatment. Carbohyd Polym 313:12088410.1016/j.carbpol.2023.120884 ↗
78. Di Prima, G.A.-O., et al., Inulin-based polymeric micelles functionalized with ocular permeation enhancers: improvement of dexamethasone permeation/penetration through bovine corneas. LID - https://doi.org/10.3390/pharmaceutics13091431 LID - 1431. (1999–4923 (Print)).10.3390/pharmaceutics13091431 ↗
79. Dong, X., et al., Multifunctional injectable hydrogel for effective promotion of cartilage regeneration and protection against osteoarthritis: combined chondroinductive, antioxidative and anti-inflammatory strategy. (1468–6996 (Print)).
80. Xu, C., et al., Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy. (1873–3476 (Electronic)).
81. Ni R et al (2020) Reactive oxygen species-responsive dexamethasone-loaded nanoparticles for targeted treatment of rheumatoid arthritis via suppressing the iRhom2/TNF-α/BAFF signaling pathway. Biomaterials 232:11973010.1016/j.biomaterials.2019.119730 ↗
82. Wang, P., et al., Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis. (1879–1344 (Electronic)).
83. Kim, H., et al., Synthesis and characterization of dexamethasone-conjugated linear polyethylenimine as a gene carrier. (1097–4644 (Electronic)).
84. Kim, H., et al., Dexamethasone-conjugated polyethylenimine as an efficient gene carrier with an anti-apoptotic effect to cardiomyocytes. (1521–2254 (Electronic)).
85. Jeon, P., et al., Dexamethasone-conjugated polyamidoamine dendrimer for delivery of the heme oxygenase-1 gene into the ischemic brain. (1616–5195 (Electronic)).
86. Hyun, H., et al., Combinational therapy of ischemic brain stroke by delivery of heme oxygenase-1 gene and dexamethasone. (1878–5905 (Electronic)).
87. Mi Bae, Y., et al., Dexamethasone-conjugated low molecular weight polyethylenimine as a nucleus-targeting lipopolymer gene carrier. (1043–1802 (Print)).
88. Hu, J.B., et al., E-selectin-targeted sialic acid-PEG-dexamethasone micelles for enhanced anti-inflammatory efficacy for acute kidney injury. (1838–7640 (Electronic)).
89. Su, M., et al., Construction of mannose-modified polyethyleneimine-block-polycaprolactone cationic polymer micelles and its application in acute lung injury. (2190–3948 (Electronic)).
90. Huang, C., et al., Construction and evaluation of novel αvβ3 integrin ligand-conjugated ultrasmall star polymer micelles targeted glomerular podocytes through GFB permeation. (1878–5905 (Electronic)).
91. Balenzano, G., et al., Cyclodextrin-based supramolecular deep eutectic solvent (CycloDES): a vehicle for the delivery of poorly soluble drugs. (1873–3476 (Electronic)).
92. Luo X, Matranga C, Tan S, Alba N, Cui XT (2011) Carbon nanotube nanoreservior for controlled release of anti-inflammatory dexamethasone. Biomaterials. 32(26):6316–2310.1016/j.biomaterials.2011.05.020 ↗
93. Wang SF, Wu YC, Cheng YC, Hu WW (2021) The development of polylactic acid/multi-wall carbon nanotubes/polyethylene glycol scaffolds for bone tissue regeneration application. Polymers. 13(11):174010.3390/polym13111740 ↗
94. Komane PP, Kumar P, Marimuthu T, Toit LC, Kondiah PP, Choonara YE, Pillay V (2018) Dexamethasone-loaded, PEGylated, vertically aligned, multiwalled carbon nanotubes for potential ischemic stroke intervention. Molecules. 23(6):140610.3390/molecules23061406 ↗
95. Zhang Y, Wang L, Sun Y, Zhu Y, Zhong Z, Shi J, Fan C, Huang Q (2013) Conjugation of dexamethasone to C60 for the design of an anti-inflammatory nanomedicine with reduced cellular apoptosis. ACS applied materials & interfaces. 5(11):5291–710.1021/am401153k ↗
96. Lan L, Zhang Q, Zhang H et al (2023) Preparation of hydroxyapatite coated porous carbon nanofibres for DEX loading and enhancing differentiation of BMSCs. RSC advances. 13(44):30898–90410.1039/D3RA02107F ↗
97. Wan C et al (2022) Novel multifunctional dexamethasone carbon dots synthesized using the one-pot green method for anti-inflammatory, osteogenesis, and osteoimmunomodulatory in bone regeneration. Biomater Sci 10(21):6291–630610.1039/D2BM01153K ↗
98. Komane PP, Kumar P, Choonara YE (2021) Atrial natriuretic peptide antibody-functionalised, PEGylated multiwalled carbon nanotubes for targeted ischemic stroke intervention. Pharmaceutics. 13(9):135710.3390/pharmaceutics13091357 ↗
99. Zhao H, Becharef S, Dumas E et al (2024) A gold nanocluster/MIL-100 (Fe) bimodal nanovector for the therapy of inflammatory disease through attenuation of Toll-like receptor signaling. Nanoscale. 16(25):12037–4910.1039/D3NR06685A ↗
100. Sun P, Zhang Q, Nie W (2019) Biodegradable mesoporous silica nanocarrier bearing angiogenic QK peptide and dexamethasone for accelerating angiogenesis in bone regeneration. ACS Biomat Sci Eng 5(12):6766–7810.1021/acsbiomaterials.9b01521 ↗